home / stock / nvsef / nvsef news


NVSEF News and Press, Novartis Ag Basel Akt From 04/16/24

Stock Information

Company Name: Novartis Ag Basel Akt
Stock Symbol: NVSEF
Market: OTC
Website: novartis.com

Menu

NVSEF NVSEF Quote NVSEF Short NVSEF News NVSEF Articles NVSEF Message Board
Get NVSEF Alerts

News, Short Squeeze, Breakout and More Instantly...

NVSEF - VGK Vs. QQQ: How Europe's 'GRANOLAS' Could Outperform The US 'Magnificent 7'

2024-04-16 14:16:55 ET Summary Just as the "Magnificent 7" stocks lead returns and headlines in US markets, an 11 stock basket called "GRANOLAS" have been called Europe's growth leaders. Here I run a head-to-head comparison using the Magnificent 7 as a proxy for the Invesco QQQ ET...

NVSEF - Vertex Pharma upgraded at Evercore on Alpine Immune deal

2024-04-11 08:36:33 ET More on Alpine Immune Sciences Alpine Immune Sciences, Inc. (ALPN) Q4 2023 Earnings Call Transcript Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug Vertex enters into agreement to acquire Alpine Immune Sciences ...

NVSEF - Bausch Health sues Amneal Pharma over Xifaxan generic

2024-04-06 09:26:54 ET More on Amneal, Bausch Health, etc. Amneal Pharmaceuticals, Inc. (AMRX) Q4 2023 Earnings Call Transcript Amneal Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation Bausch Health: A Timely Divestiture Is The Key To An Higher Val...

NVSEF - Novartis: Higher Guidance, Now A Buy

2024-04-04 00:56:46 ET Summary Novartis is now a pure player in innovative medicines. Despite a negative FX, the company reported solid 2023 financial results and increased its dividend per share. There is a strategic rationale for acquiring MorphoSys AG. NVS had raised its ou...

NVSEF - Intra-Cellular files lawsuits challenging Caplyta generics

2024-04-02 15:38:04 ET More on Intra-Cellular Therapies Intra-Cellular Therapies Is On Fire Intra-Cellular Therapies, Inc. (ITCI) Q4 2023 Earnings Call Transcript Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy' I...

NVSEF - Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval

2024-03-31 09:25:35 ET Summary The positive CHMP opinion could mean possible European Approval; European Commission expected to decide upon approval for this in the next few months. Phase 3 NORSE EIGHT study underway using ONS-5010 for the treatment of patients with Wet-AMD; Data ...

NVSEF - Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

2024-03-28 17:59:49 ET Summary OLEMA Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted oncology therapies, with a focus on women's cancer. Their flagship drug, palazestrant, shows promising results for halting the progression of estrogen receptor-po...

NVSEF - DFIV: When Value, Growth And Yield Come Together

2024-03-27 10:08:08 ET Summary Dimensional International Value ETF is an actively managed fund investing in companies with value characteristics outside the U.S. The portfolio is well-diversified across holdings, but quite heavy in Japanese companies and in financials. Not onl...

NVSEF - Week In Review: 3 Multinationals Plan Investments In Southeast Asia Facilities

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

NVSEF - AstraZeneca-Fusion deal reignites radiopharma space

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...

Previous 10 Next 10